Polymer conjugate of folic acid or folic acid derivative
Disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein an amide bond is not used. The compound has chemical stability and adequate drug release rate in the living organism. Specifically disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein a substituent represented by formula (I) is bonded to a carboxy group of a block copolymer which is composed of a polyethylene glycol and a polymer having a carboxy group in a side chain, or a pharmacologically acceptable salt thereof. [In the formula, A represents a monocyclic or fused aromatic group; G represents an optionally substituted (C1-C6) alkylene group; Y represents a hydrogen atom or a substituent; and E represents a residue of folic acid or a folic acid derivative.]
1. A polymer conjugate of methotrexate or pemetrexed or a pharmacologically acceptable salt thereof, in which the nitrogen atom bound to the group represented by G of a substituent represented by the following formula (I) is amid-linked to a carboxy group of a side chain of a block copolymer comprising a polyethylene glycol and polyaspartic acid or polygutamic acid:
wherein A represents a monocyclic or fused aromatic group; G represents a (C1-C6) alkylene group which may be substituted; Y represents a hydrogen atom or a substituent; and E represents a residue of methotrexate or pemetrexed.
2. The polymer conjugate of methotrexate or pemetrexed or a pharmacologically acceptable salt thereof according to claim 1 , which is represented by the following formula (II):
wherein D represents an unsubstituted (C1-C6) alkyl group; a mean value of n is 50 to 1000; J represents a (C2-C6) alkylene group; a mean value of c+d+e is 5 to 100, while c+d represents an integer; R represents a hydroxy group or the substituent represented by the formula (I), whereas at least one of R in one molecule is the substituent represented by the formula (I); and B represents a (C1-C6) acyl group.
3. The polymer conjugate of methotrexate or pemetrexed or a pharmacologically acceptable salt thereof according to claim 1 , wherein the substituent represented by the formula (I) is a substituent represented by the following formula (III):
wherein E represents a residue of methotrexate or pemetrexed.
4. An anticancer drug comprising, as an active ingredient, the polymer conjugate of methotrexate or pemetrexed or a pharmacologically acceptable salt thereof according to claim 1 , 2 , or 3 .
5. A therapeutic drug for inflammatory diseases comprising, as an active ingredient, the polymer conjugate of methotrexate or pemetrexed or a pharmacologically acceptable salt thereof according to claim 1 , 2 or 3 .
6. The polymer conjugate of methotrexate or pemetrexed of claim 1 , wherein a mixture of the α-substituted regioisomer of the substituent of formula (I) linked to said methotrexate or pemetrexed and the γ-substituted regioisomer of the substituent of formula (I) linked to said methotrexate or pemetrexed is bound to said polymer conjugate.